Continue As A Guest
Updata
Hey! Thank you so much for your support and quality posts for V Show!
And congratulations on becoming our Vipon Associated Editor.
From now on, in addition to getting 10 points for each post (up to 30 points daily), we will regularly review each of your articles, and each approved article (tagged with Featured label) will be paid an additional $50.
Note: Not all articles you posted will get $50, only those that meet our requirements will be paid, and articles or contents that do not meet the requirements will be removed.
Please continue to produce high quality content for organic likes. Our shoppers love seeing your stories & posts!
Congratulations! Your V SHOW post Planting Tips has become our Featured content, we will pay $50 for this post. Please check on your balance. Please continue to produce high quality original content!
The global liquid biopsy market was valued at USD 8.01 billion in 2023 and is projected to grow from USD 9.63 billion in 2024 to USD 58.64 billion by 2032, registering a robust CAGR of 25.3% over the forecast period. In 2023, North America dominated the market, capturing a 54.43% share.
The liquid biopsy market is set for substantial growth, propelled by the rising global prevalence of various cancers. According to Fortune Business Insights™ in its report "Liquid Biopsy Market, 2021-2028," the surge in cancers such as lung and stomach cancer is driving demand for advanced diagnostic solutions like liquid biopsy. This minimally invasive technique, which analyzes blood samples to obtain vital cancer-related insights, is becoming an essential tool in oncology, accelerating market expansion.
Request a Free Sample PDF:
https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/liquid-biopsy-market-102506
Market Segmentation:
By Product Analysis
Assay Kits Driving Market Share
The kits & reagents segment led the market in 2024, fueled by the launch of advanced diagnostic assay kits offering faster and more reliable results. Key developments include Illumina’s TruSight Oncology 500 ctDNA kit (Nov 2023) and Guardant Health’s Guardant Reveal test (Feb 2021) for early-stage colorectal cancer monitoring. Growing approvals and favorable reimbursement policies are further boosting the segment. For instance, the FDA expanded the approval of FoundationOne Liquid CDx for breast and ovarian cancers in 2021. Meanwhile, the instruments segment is set for moderate growth, supported by new launches like Thermo Fisher’s QuantStudio Absolute Q digital PCR system (Sept 2021).
By Application Analysis
NIPT Segment Leads, Oncology to See Rapid Growth
Non-Invasive Prenatal Testing (NIPT) dominated in 2024, driven by rising cases of genetic abnormalities such as Down syndrome and increasing adoption of advanced prenatal tests like Yourgene’s IONA care (May 2021). The oncology segment is expected to grow at a faster pace, supported by early cancer detection initiatives and product expansions like Guardant Health’s Guardant360 Response test (June 2021).
By End User Analysis
Hospitals Dominate, Labs Gaining Traction
Hospitals held the largest market share in 2024 due to the rising demand for cancer diagnostics and prenatal testing, particularly in emerging markets. Reports indicate 25–30% of pregnant women in Australia opt for NIPT in private hospitals. Clinical laboratories are anticipated to grow steadily, supported by the increasing number of labs offering liquid biopsy tests globally, with over 200,000 labs operating in the U.S. alone.
Key Companies Featured in the Liquid Biopsy Market Report:
Restraining Factors:
Regional Insights:
North America: The liquid biopsy market in North America is expected to grow significantly, driven by expanding applications and increased research and development efforts in the region.
Europe: The European market is anticipated to expand at a steady pace, fueled by the rising prevalence of cancer and growing awareness of liquid biopsy among the population.
Competitive Landscape:
Technological Advancements Driving Intense Market Competition:
Key players in the liquid biopsy market are focusing on integrating cutting-edge technologies to enhance cancer diagnostics and treatment. The adoption of advanced techniques aims to improve disease detection and management, ultimately reducing the severity of life-threatening conditions. This continuous innovation is fueling competition among leading companies, enabling them to expand their market reach and strengthen their industry presence.
Key Industry Developments:
June 2021: Illumina Inc. and Next Generation Genomic Co., Ltd. introduced VeriSeq NIPT Solution v2 in Southeast Asia.
The global liquid biopsy market was valued at USD 8.01 billion in 2023 and is projected to grow from USD 9.63 billion in 2024 to USD 58.64 billion by 2032, registering a robust CAGR of 25.3% over the forecast period. In 2023, North America dominated the market, capturing a 54.43% share.
The liquid biopsy market is set for substantial growth, propelled by the rising global prevalence of various cancers. According to Fortune Business Insights™ in its report "Liquid Biopsy Market, 2021-2028," the surge in cancers such as lung and stomach cancer is driving demand for advanced diagnostic solutions like liquid biopsy. This minimally invasive technique, which analyzes blood samples to obtain vital cancer-related insights, is becoming an essential tool in oncology, accelerating market expansion.
Request a Free Sample PDF:
https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/liquid-biopsy-market-102506
Market Segmentation:
By Product Analysis
Assay Kits Driving Market Share
The kits & reagents segment led the market in 2024, fueled by the launch of advanced diagnostic assay kits offering faster and more reliable results. Key developments include Illumina’s TruSight Oncology 500 ctDNA kit (Nov 2023) and Guardant Health’s Guardant Reveal test (Feb 2021) for early-stage colorectal cancer monitoring. Growing approvals and favorable reimbursement policies are further boosting the segment. For instance, the FDA expanded the approval of FoundationOne Liquid CDx for breast and ovarian cancers in 2021. Meanwhile, the instruments segment is set for moderate growth, supported by new launches like Thermo Fisher’s QuantStudio Absolute Q digital PCR system (Sept 2021).
By Application Analysis
NIPT Segment Leads, Oncology to See Rapid Growth
Non-Invasive Prenatal Testing (NIPT) dominated in 2024, driven by rising cases of genetic abnormalities such as Down syndrome and increasing adoption of advanced prenatal tests like Yourgene’s IONA care (May 2021). The oncology segment is expected to grow at a faster pace, supported by early cancer detection initiatives and product expansions like Guardant Health’s Guardant360 Response test (June 2021).
By End User Analysis
Hospitals Dominate, Labs Gaining Traction
Hospitals held the largest market share in 2024 due to the rising demand for cancer diagnostics and prenatal testing, particularly in emerging markets. Reports indicate 25–30% of pregnant women in Australia opt for NIPT in private hospitals. Clinical laboratories are anticipated to grow steadily, supported by the increasing number of labs offering liquid biopsy tests globally, with over 200,000 labs operating in the U.S. alone.
Key Companies Featured in the Liquid Biopsy Market Report:
Restraining Factors:
Regional Insights:
North America: The liquid biopsy market in North America is expected to grow significantly, driven by expanding applications and increased research and development efforts in the region.
Europe: The European market is anticipated to expand at a steady pace, fueled by the rising prevalence of cancer and growing awareness of liquid biopsy among the population.
Competitive Landscape:
Technological Advancements Driving Intense Market Competition:
Key players in the liquid biopsy market are focusing on integrating cutting-edge technologies to enhance cancer diagnostics and treatment. The adoption of advanced techniques aims to improve disease detection and management, ultimately reducing the severity of life-threatening conditions. This continuous innovation is fueling competition among leading companies, enabling them to expand their market reach and strengthen their industry presence.
Key Industry Developments:
June 2021: Illumina Inc. and Next Generation Genomic Co., Ltd. introduced VeriSeq NIPT Solution v2 in Southeast Asia.
Are you sure you want to stop following?
Congrats! You are now a member!
Start requesting vouchers for promo codes by clicking the Request Deal buttons on products you want.
Start requesting vouchers for promo codes by clicking the Request Deal buttons on products you want.
Sellers of Amazon products are required to sign in at www.amztracker.com
More information about placing your products on this site can be found here.
Are you having problems purchasing a product with the supplied voucher? If so, please contact the seller via the supplied email.
Also, please be patient. Sellers are pretty busy people and it can take awhile to respond to your emails.
After 2 days of receiving a voucher you can report the seller to us (using the same button) if you cannot resolve this issue with the seller.
For more information click here.
We have taken note and will also convey the problems to the seller on your behalf.
Usually the seller will rectify it soon, we suggest now you can remove this request from your dashboard and choose another deal.
If you love this deal most, we suggest you can try to request this deal after 2 days.
This will mark the product as purchased. The voucher will be permanently removed from your dashboard shortly after. Are you sure?
You are essentially competing with a whole lot of other buyers when requesting to purchase a product. The seller only has a limited amount of vouchers to give out too.
Select All Groups
✕
Adult Products
Arts, Crafts & Sewing
Automotive & Industrial
Beauty & Grooming
Cell Phones & Accessories
Electronics & Office
Health & Household
Home & Garden
Jewelry
Kitchen & Dining
Men's Clothing & Shoes
Pet Supplies
Sports & Outdoors
Toys, Kids & Baby
Watches
Women's Clothing & Shoes
Other
Adult Products
©Copyright 2025 Vipon All Right Reserved · Privacy Policy · Terms of Service · Do Not Sell My Personal Information
Certain content in this page comes from Amazon. The content is provided as is, and is subject
to change or removal at
any time. Amazon and the Amazon logo are trademarks of Amazon.com,
Inc. or its affiliates.
Comments